Drug Trial Radar · NCT07412236
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,208
Planned (sponsor's estimate)
Start
Mar 23, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase).
Conditions
- Liver Fibrosis
- Liver Fibrosis in Chronic Hepatitis B
Interventions
Hydronidone (270mg)Drug
Dosage: 30 mg/capsule, three capsules taken three times daily, resulting in a total daily therapeutic dose of 270 mg. The medication is administered orally half an hour before meals.
Hydronidone (Placebo Group)Drug
Dosage: three capsules taken three times daily.The medication is administered orally half an hour before meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Clinical Endpoint EventsTime frame: From the first dose administration to the end of the treatment period (Week 261).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.